Integrative analysis of T cell-mediated tumor killing-related genes reveals KIF11 as a novel therapeutic target in esophageal squamous cell carcinoma
The TTKPI is a promising biomarker for accurately determining survival and predicting the effectiveness of immunotherapy in ESCC patients. This risk indicator can help patients receive timely and precise early intervention, thereby advancing personalized medicine and facilitating precise immuno-oncology research. KIF11 plays a crucial role in driving tumor proliferation and migration and may act as a potential tumor biomarker of ESCC.
Authors
- Xinxin Cheng (ORCID: https://orcid.org/0000-0001-6485-8960)
- Qingjie Min (ORCID: https://orcid.org/0000-0003-4140-600X)
- Liping Yan (ORCID: https://orcid.org/0000-0002-2285-5048)
- Zhangwang Li (ORCID: https://orcid.org/0000-0001-9625-2736)
- Huihui Zhao (ORCID: https://orcid.org/0000-0002-7607-3527)
- Qimin Zhan
- Qingnan Wu (ORCID: https://orcid.org/0000-0002-1469-941X)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Peking University International Hospital (CN)
- Ministry of Education (ET)
- University of South China (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1186/s12967-025-06178-y
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 6.27
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China